Germany’s final depemokimab decision highlights the evidentiary cost of an active-biologic comparator gap in severe nasal polyposis. https://www.mattheneus.com/editorial/g-ba-depemokimab-crswnp-final-resolution-active-biologic-comparator-gap-2026-10-01 #HTA #Pharma #RegulatoryAffairs
#regulatoryaffairs — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #regulatoryaffairs, aggregated by home.social.